Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer

November 25th 2021

Bryson Katona, MD, discusses the hallmarks of hereditary diffuse gastric cancer.

Sequencing Systemic Therapy for Advanced HCC

November 24th 2021

Andrea Casadei Gardini, MD, leads the discussion on the optimal sequencing of systemic therapy for advanced HCC.

Optimizing the Selection of Frontline TKIs for Advanced HCC

November 24th 2021

Experts in gastroenterology share their approaches to first-line single-agent and combination TKI therapies for the treatment of advanced HCC.

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

November 23rd 2021

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Dr. Iqbal on the Emergence of Checkpoint Inhibitors in Upper GI Cancers

November 23rd 2021

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors

November 23rd 2021

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

November 22nd 2021

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Dr. Hochster on Treatment Considerations for HER2+ Gastric Cancer

November 22nd 2021

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

November 22nd 2021

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

Influx of Therapies in NETs Prompts Questions Over Combinations and Sequencing

November 19th 2021

Diane Reidy-Lagunes, MD, unpacked recent updates in neuroendocrine tumors.

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

A New Frontier in Cholangiocarcinoma Management and Treatment

November 18th 2021

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs

November 17th 2021

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Updates to First-line Treatment Options for Advanced HCC

November 17th 2021

Andrea Casadei Gardini, MD, presents the case of a 63-year-old man diagnosed with advanced HCC, and the panel reviews available first-line treatment options for patients with advanced HCC.

Is There a Role for Systemic Therapy for Patients With Intermediate HCC?

November 17th 2021

Gastroenterology experts discuss whether there a is a role for systemic therapy for the management of intermediate HCC.

FDA Grants Orphan Drug Designation to Toripalimab for Esophageal Cancer

November 16th 2021

The FDA granted an orphan drug designation to toripalimab for the treatment of patients with esophageal cancer.

Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer

November 15th 2021

Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the potential to further inform treatment selection and sequencing in the field

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

November 15th 2021

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas

November 15th 2021

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

Telotristat Ethyl Improves Symptoms and Patient Satisfaction in Carcinoid Syndrome

November 15th 2021

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.